The US Patent and Trademark Office (USPTO) has granted notice of allowance (NOA) to molecular diagnostics company Vermillion for a patent related to biomarker alpha1beta glycoprotein and biomarker combinations that include alpha1beta glycoprotein for the diagnosis of peripheral artery disease (PAD).
Vermillion CEO Gail Page said this will be their third patent for biomarkers that can be used for the diagnosis of PAD.
"Expanding our intellectual property portfolio helps protect the potential value of our PAD program as we progress our clinical studies," Page said.
Vermillion develops diagnostic tests for oncology, hematology, cardiology and women’s health and aids physicians to diagnose, treat and improve outcomes for patients.